Sound journalism, grounded in facts and Biblical truth

U.S. health officials question AstraZeneca data

A vial and syringes of the AstraZeneca COVID-19 vaccine in Luton, England, on Sunday Associated Press/Photo by Alberto Pezzali

U.S. health officials question AstraZeneca data

The British-Swedish drugmaker plans to apply in the coming weeks for its COVID-19 vaccine to receive emergency use authorization in the United States. On Monday, AstraZeneca announced a study of mostly Americans showed the shot was 79 percent effective at preventing symptomatic cases of the disease. But just after midnight, the U.S. National Institutes of Health released a statement saying the company “may have included outdated information from the trial.”

What does this mean for the vaccine? AstraZeneca said it would release more up-to-date information within 48 hours. In addition to analysis from the NIH’s data and safety monitoring board, the U.S. Food and Drug Administration will also review and debate the evidence from AstraZeneca before deciding whether to allow its use in the country. Three other COVID-19 vaccines have already received emergency use authorization from the FDA. When reporters have asked, AstraZeneca has declined to release a breakdown of the 141 cases it said proved the vaccine is effective.

Dig deeper: Read John Dawson’s report in Beginnings explaining the differences between the three COVID-19 vaccines currently available in the United States.

Rachel Lynn Aldrich Rachel is an assistant editor for WORLD Digital. She is a Patrick Henry College and World Journalism Institute graduate. Rachel resides with her husband in Wheaton, Ill.


Please wait while we load the latest comments...


Please register or subscribe to comment on this article.


All people who are not citizens of the U.S. should be vaccinated before entering. It doesn't have to be AstraZeneca.